Objectives:

Andalusian Health Service (AHS) established the RP4 program, based on the review of potential prescription problems (PPPs) in order to improve patient's safety. Some of these PPPs are related to kidney damage (PPPKDs). The main objective of this study is to evaluate the percentage of acceptance of the pharmaceutical intervention (PI) developed in a Health Management Area (HMA) for reducing PPPKDs. We also aimed to describe these PPPKDS and to analyze the evolution of these data between 2015-2019.

Methods:

Retrospective study conducted by the Pharmacy Service of an HMA which offers health coverage to 406,768 patients. All the PPPKDs detected in these patients were included. Data were collected through an AHS Web Application. A descriptive analysis of variables was developed.

Results:

In 2019, 466 PPPKDs (involving 460 patients) were detected. Overall percentage of acceptance of the PI was 90.7% and, according to type of PPPKD, was: 92.8% for NSAIDs duplication, 90.7% for double renin-angiotensinaldosterone system (RAAS) blockade and 89.8% for triple Whammy.

During 2015-2019, detected PPPKDs have decreased from 634 to 466, and the percentage of acceptance has been adequate every year.

Conclusion:

The acceptance of the PI, framed in the RP4 program, was optimal. The number of PPPKDs detected has decreased and the percentage of acceptance has remained elevated during the study period, which would support the utility of this program for the improvement of patients' safety.

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )